Haemonetics (NYSE:HAE) Price Target Increased to $110.00 by Analysts at Mizuho

Haemonetics (NYSE:HAE – Get Rating) had its target price hoisted by Mizuho from $100.00 to $110.00 in a report issued on Tuesday morning, The Fly reports. Mizuho currently has a buy rating on the medical instruments supplier’s stock.

HAE has been the topic of a number of other research reports. Citigroup lifted their price objective on Haemonetics from $88.00 to $92.00 and gave the company a neutral rating in a report on Monday, December 12th. StockNews.com began coverage on Haemonetics in a report on Wednesday, October 12th. They issued a buy rating on the stock. Barrington Research lifted their price target on shares of Haemonetics from $88.00 to $94.00 and gave the company an outperform rating in a research report on Tuesday, November 8th. TheStreet upgraded shares of Haemonetics from a c+ rating to a b rating in a research report on Monday, November 7th. Finally, Raymond James lifted their price target on shares of Haemonetics from $88.00 to $100.00 and gave the company an outperform rating in a research report on Tuesday, November 8th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $97.50.

Haemonetics Stock Performance

NYSE HAE opened at $90.60 on Tuesday. The company has a quick ratio of 1.76, a current ratio of 2.73 and a debt-to-equity ratio of 1.04. Haemonetics has a 52-week low of $43.50 and a 52-week high of $91.36. The business’s 50-day moving average price is $81.62 and its 200 day moving average price is $77.20. The firm has a market cap of $4.59 billion, a P/E ratio of 54.58 and a beta of 0.39.

Haemonetics (NYSE:HAE – Get Rating) last announced its quarterly earnings data on Monday, November 7th. The medical instruments supplier reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.70 by $0.13. Haemonetics had a return on equity of 20.05% and a net margin of 7.94%. The company had revenue of $297.49 million for the quarter, compared to analyst estimates of $273.92 million. On average, equities research analysts expect that Haemonetics will post 2.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Cardinal Capital Management raised its position in shares of Haemonetics by 2.3% during the 4th quarter. Cardinal Capital Management now owns 10,780 shares of the medical instruments supplier’s stock worth $848,000 after purchasing an additional 238 shares during the last quarter. Romano Brothers AND Company acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $31,000. Riverwater Partners LLC acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $717,000. North Star Investment Management Corp. acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $739,000. Finally, Bank of New York Mellon Corp raised its position in shares of Haemonetics by 3.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 614,235 shares of the medical instruments supplier’s stock worth $45,472,000 after purchasing an additional 17,929 shares during the last quarter.

Haemonetics Company Profile

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.